Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M281,048Revenue $M74,331Net Margin (%)21.6Altman Z-Score5.3
Enterprise Value $M268,712EPS $5.7Operating Margin %28.1Piotroski F-Score6
P/E(ttm)18.1Beneish M-Score-2.6Pre-tax Margin (%)28.2Higher ROA y-yN
Price/Book4.210-y EBITDA Growth Rate %4.3Quick Ratio2.1Cash flow > EarningsY
Price/Sales3.95-y EBITDA Growth Rate %3.5Current Ratio2.4Lower Leverage y-yN
Price/Free Cash Flow21.0y-y EBITDA Growth Rate %16.9ROA % (ttm)12.1Higher Current Ratio y-yY
Dividend Yield %2.8PEG5.2ROE % (ttm)21.6Less Shares Outstanding y-yY
Payout Ratio %50.0Shares Outstanding M2,773ROIC % (ttm)27.1Gross Margin Increase y-yY

Gurus Latest Trades with JNJ

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
JNJTweedy Browne 2015-03-31 Reduce-0.23%$98.32 - $106.39
($101.69)
$ 101.35-0%Reduce 2.09%4,055,962
JNJMichael Price 2015-03-31 Reduce-0.13%$98.32 - $106.39
($101.69)
$ 101.35-0%Reduce 28.57%25,000
JNJYacktman Focused Fund 2015-03-31 Reduce-0.11%$98.32 - $106.39
($101.69)
$ 101.35-0%Reduce 3.23%3,000,000
JNJDonald Yacktman 2015-03-31 Reduce-0.08%$98.32 - $106.39
($101.69)
$ 101.35-0%Reduce 2.08%8,432,672
JNJJames Barrow 2015-03-31 Add0.03%$98.32 - $106.39
($101.69)
$ 101.35-0%Add 1.19%15,676,362
JNJJohn Rogers 2015-03-31 Add0.03%$98.32 - $106.39
($101.69)
$ 101.35-0%Add 3.95%657,074
JNJJoel Greenblatt 2015-03-31 Add0.03%$98.32 - $106.39
($101.69)
$ 101.35-0%Add 5.40%833,196
JNJRichard Pzena 2015-03-31 Reduce-0.01%$98.32 - $106.39
($101.69)
$ 101.35-0%Reduce 0.84%1,174,016
JNJKen Fisher 2015-03-31 Add0.01%$98.32 - $106.39
($101.69)
$ 101.35-0%Add 0.31%10,456,816
JNJMario Gabelli 2015-03-31 Reduce$98.32 - $106.39
($101.69)
$ 101.35-0%Reduce 1.12%333,155
JNJRuane Cunniff 2015-03-31 Reduce$98.32 - $106.39
($101.69)
$ 101.35-0%Reduce 0.01%75,937
JNJFirst Eagle Investment 2015-03-31 Add$98.32 - $106.39
($101.69)
$ 101.35-0%Add 0.67%1,627,823
JNJDodge & Cox 2015-03-31 Reduce$98.32 - $106.39
($101.69)
$ 101.35-0%Reduce 9.61%39,985
JNJJoel Greenblatt 2014-12-31 Add0.66%$96.78 - $109.07
($105.43)
$ 101.35-4%Add 5420.84%790,529
JNJRobert Olstein 2014-12-31 Reduce-0.17%$96.78 - $109.07
($105.37)
$ 101.35-4%Reduce 14.46%71,000
JNJJohn Rogers 2014-12-31 Add0.11%$96.78 - $109.07
($105.37)
$ 101.35-4%Add 17.80%632,132
JNJHOTCHKIS & WILEY 2014-12-31 Sold Out $96.78 - $109.07
($105.37)
$ 101.35-4%Sold Out0
JNJHOTCHKIS & WILEY 2014-09-30 Reduce-0.53%$99.82 - $108.64
($103.64)
$ 101.35-2%Reduce 99.80%2,862
JNJJames Barrow 2014-09-30 Reduce-0.24%$99.82 - $108.64
($103.64)
$ 101.35-2%Reduce 10.05%15,350,650
JNJYacktman Focused Fund 2014-09-30 Reduce-0.21%$99.82 - $108.64
($103.64)
$ 101.35-2%Reduce 6.06%3,100,000
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

JNJ is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


JNJ: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Stoffels PaulusChief Scientific Officer 2015-04-28Sell187,250$100.730.62view
Fasolo PeterVP, Global Human Resources 2015-03-05Sell115,307$102.4-1.03view
COSGROVE STEPHEN JCorporate Controller 2014-11-05Sell2,490$108.55-6.63view
Ullmann Michael HVP, General Counsel 2014-10-31Sell17,350$107.43-5.66view
CULLEN JAMESDirector 2014-09-10Sell2,446$104.12-2.66view
Caruso Dominic JVP, Finance; CFO 2014-08-21Sell30,000$104.3-2.83view
COSGROVE STEPHEN JCorporate Controller 2014-05-05Sell22,000$100.051.3view
Fasolo PeterVP, Global Human Resources 2014-03-14Sell6,824$93.158.8view
COSGROVE STEPHEN JCorporate Controller 2013-08-14Sell17,200$91.3910.9view
Ullmann Michael HVP, General Counsel 2013-08-05Sell16,140$93.688.19view

Press Releases about JNJ :

    Quarterly/Annual Reports about JNJ:

    News about JNJ:

    Articles On GuruFocus.com
    Johnson & Johnson Drug Pipeline to Help it Deliver Above-Average Growth May 22 2015 
    UBS and JMP Securities Downgrade Achillion Pharmaceuticals Inc.(ACHN) Following Johnson & Johnson (J May 21 2015 
    International Diversification May Be Closer than You Think May 20 2015 
    Dycom Industries (DY) Surpasses Estimates; Achillion Pharma (ACHN) Inks Mega-Deal with Janssen May 20 2015 
    Sector Allocation As It Pertains To Dividend Growth Investing May 19 2015 
    Ken Fisher Adds to His Johnson and Johnson Position May 16 2015 
    Johnson & Johnson A Good Investment Despite Current Lows May 14 2015 
    10 Small/Mid-Cap Dividend Growth Stocks Answering The Call May 13 2015 
    Free Cash Flow Payout vs. Dividend Payout May 06 2015 
    Hope Is Not A Strategy: Have A Precise Calculation Of Return In Mind Before Investing May 04 2015 

    More From Other Websites
    Johnson & Johnson Seeks to Deliver 10 Blockbusters May 22 2015
    The 4 Stocks That Sank the DJIA on Friday May 22 2015
    Reckitt faces regulatory friction in UK over K-Y acquisition May 22 2015
    UK watchdog says Reckitt's K-Y buy could hurt competition May 22 2015
    UK watchdog says Reckitt's K-Y buy could hurt competition May 22 2015
    UK watchdog says Reckitt's K-Y buy could hurt competition May 22 2015
    Hedge Funds Keep Betting Big On Health Care May 21 2015
    JOHNSON & JOHNSON Files SEC form 8-K, Change in Directors or Principal Officers May 21 2015
    J&J Pays Millions to Settle Billion-Dollar Risperdal Case May 21 2015
    J&J (JNJ) to File for More than 10 New Products by 2019 - Analyst Blog May 21 2015
    Stocks across all generations May 21 2015
    S&P 500 Index Futures Trading Higher May 21 2015
    Johnson & Johnson meets investors May 21 2015
    Johnson & Johnson: Here's Where the Growth Will Come From May 21 2015
    Raymond James: Johnson & Johnson Has 'Innovation' May 21 2015
    3 Big Pharmaceutical Stocks to Buy Right Now May 21 2015
    What Does The Johnson & Johnson/Achillion Deal Mean For HCV Competitors? May 21 2015
    Apple or Microsoft? How to Build a One-Stock Portfolio May 21 2015
    Johnson & Johnson expects lucrative return on drug pipeline May 20 2015
    Johnson & Johnson expects lucrative return on drug pipeline May 20 2015

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    Gurufocus
    ReplyGurufocus - 1 year ago
    test
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    FEEDBACK